WO2005058028A3 - Novel gene disruptions, compositions and methods relating thereto - Google Patents

Novel gene disruptions, compositions and methods relating thereto Download PDF

Info

Publication number
WO2005058028A3
WO2005058028A3 PCT/US2004/041721 US2004041721W WO2005058028A3 WO 2005058028 A3 WO2005058028 A3 WO 2005058028A3 US 2004041721 W US2004041721 W US 2004041721W WO 2005058028 A3 WO2005058028 A3 WO 2005058028A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
compositions
abnormalities
methods relating
disruptions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/041721
Other languages
French (fr)
Other versions
WO2005058028A2 (en
Inventor
Stephen Anderson
Jane Brennan
Frederic Desauvage
Zhiyong Ding
Joel Edwards
Nelda Fikes
Wenhu Huang
Wenjun Ouyang
Carolina Rangel
Mamta Sangha
Zheng-Zheng Shi
Mary Jean Sparks
Joseph Trackey
Melissa Vetter
Ching-Yun Wang
Jessica Woodings
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Lexicon Pharmaceuticals Inc
Original Assignee
Genentech Inc
Lexicon Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Lexicon Genetics Inc filed Critical Genentech Inc
Priority to AU2004299044A priority Critical patent/AU2004299044B2/en
Priority to EP04813966A priority patent/EP1694116A2/en
Priority to CA002550117A priority patent/CA2550117A1/en
Priority to US10/583,466 priority patent/US8067664B2/en
Priority to JP2006545780A priority patent/JP2007518404A/en
Publication of WO2005058028A2 publication Critical patent/WO2005058028A2/en
Publication of WO2005058028A3 publication Critical patent/WO2005058028A3/en
Anticipated expiration legal-status Critical
Priority to AU2008234961A priority patent/AU2008234961A1/en
Priority to US13/317,754 priority patent/US20120174239A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Environmental Sciences (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO224, PRO9783, PRO1108, PRO34000, PRO240, PRO943, hu A33, PRO230, PRO178, PRO1199, PRO4333, PRO1336, PRO19598, PRO1083, hu TRPM2 or PRO1801 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.
PCT/US2004/041721 2003-12-16 2004-12-13 Novel gene disruptions, compositions and methods relating thereto Ceased WO2005058028A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2004299044A AU2004299044B2 (en) 2003-12-16 2004-12-13 Novel gene disruptions, compositions and methods relating thereto
EP04813966A EP1694116A2 (en) 2003-12-16 2004-12-13 Novel gene disruptions, compositions and methods relating thereto
CA002550117A CA2550117A1 (en) 2003-12-16 2004-12-13 Novel gene disruptions, compositions and methods relating thereto
US10/583,466 US8067664B2 (en) 2003-12-16 2004-12-13 PRO224 gene disruptions, and methods related thereto
JP2006545780A JP2007518404A (en) 2003-12-16 2004-12-13 Novel gene disruption, compositions and methods relating thereto
AU2008234961A AU2008234961A1 (en) 2003-12-16 2008-10-24 Novel gene disruptions, compositions and methods relating thereto
US13/317,754 US20120174239A1 (en) 2003-12-16 2011-10-27 Novel PRO1199 gene disruptions, and methods relating thereto

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53004303P 2003-12-16 2003-12-16
US60/530,043 2003-12-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/317,754 Division US20120174239A1 (en) 2003-12-16 2011-10-27 Novel PRO1199 gene disruptions, and methods relating thereto

Publications (2)

Publication Number Publication Date
WO2005058028A2 WO2005058028A2 (en) 2005-06-30
WO2005058028A3 true WO2005058028A3 (en) 2006-05-18

Family

ID=34700085

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/041721 Ceased WO2005058028A2 (en) 2003-12-16 2004-12-13 Novel gene disruptions, compositions and methods relating thereto

Country Status (7)

Country Link
US (2) US8067664B2 (en)
EP (1) EP1694116A2 (en)
JP (1) JP2007518404A (en)
AU (2) AU2004299044B2 (en)
CA (1) CA2550117A1 (en)
WO (1) WO2005058028A2 (en)
ZA (4) ZA200801231B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9020572B2 (en) 2008-02-21 2015-04-28 Dexcom, Inc. Systems and methods for processing, transmitting and displaying sensor data
US11021711B2 (en) 2008-03-14 2021-06-01 Genentech, Inc. Genetic variations associated with drug resistance

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012963A2 (en) 1997-09-12 1999-03-18 Biogen, Inc. Cysteine rich receptors: trail
EP1487877B1 (en) 2001-09-18 2010-10-27 Genentech, Inc. Compositions and methods for the diagnosis of tumors
WO2005103720A1 (en) * 2004-03-29 2005-11-03 Medstar Research Institute, Inc. Methods of diagnosing cardiovascular disease
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
WO2006026222A2 (en) 2004-08-25 2006-03-09 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US7931902B2 (en) 2005-08-15 2011-04-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US20080311107A1 (en) * 2006-02-17 2008-12-18 Genetech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
US20110200579A1 (en) * 2007-01-23 2011-08-18 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
PT2251454E (en) 2009-05-13 2014-10-01 Sio2 Medical Products Inc Vessel coating and inspection
US9878101B2 (en) 2010-11-12 2018-01-30 Sio2 Medical Products, Inc. Cyclic olefin polymer vessels and vessel coating methods
WO2013033513A1 (en) 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
CA2855353C (en) 2011-11-11 2021-01-19 Sio2 Medical Products, Inc. Passivation, ph protective or lubricity coating for pharmaceutical package, coating process and apparatus
EP2814496B1 (en) 2012-02-17 2018-04-11 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
WO2014078666A1 (en) 2012-11-16 2014-05-22 Sio2 Medical Products, Inc. Method and apparatus for detecting rapid barrier coating integrity characteristics
US9764093B2 (en) 2012-11-30 2017-09-19 Sio2 Medical Products, Inc. Controlling the uniformity of PECVD deposition
AU2013352436B2 (en) 2012-11-30 2018-10-25 Sio2 Medical Products, Inc. Controlling the uniformity of PECVD deposition on medical syringes, cartridges, and the like
US9662450B2 (en) 2013-03-01 2017-05-30 Sio2 Medical Products, Inc. Plasma or CVD pre-treatment for lubricated pharmaceutical package, coating process and apparatus
US9937099B2 (en) 2013-03-11 2018-04-10 Sio2 Medical Products, Inc. Trilayer coated pharmaceutical packaging with low oxygen transmission rate
EP2792742A1 (en) 2013-04-17 2014-10-22 Universitätsklinikum Hamburg-Eppendorf (UKE) Gene-therapy vectors for treating cardiomyopathy
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
WO2015148471A1 (en) 2014-03-28 2015-10-01 Sio2 Medical Products, Inc. Antistatic coatings for plastic vessels
EP3115784A1 (en) * 2015-07-10 2017-01-11 Koss, Michael Janusz Polypeptide marker for analysis, diagnosis and therapy of eye-related diseases
CN106797916A (en) * 2017-01-24 2017-06-06 黄山市休宁县珍稀水生动物研究所 A kind of Platysternon megacephalum Gray cultural method
WO2018178296A1 (en) * 2017-03-29 2018-10-04 Stichting Sanquin Bloedvoorziening Isolation of stable regulatory t cells and uses thereof
CN110692594B (en) * 2019-10-12 2021-12-24 上海交通大学 Human hemangioma animal model and high-success-rate construction method thereof
CN111742883B (en) * 2020-01-03 2022-02-18 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） A method for constructing an animal model of allergic rhinitis with lung and spleen deficiency syndrome
CN113080136B (en) * 2021-02-24 2022-05-17 厦门大学 Method for establishing retroperitoneal sarcoma mouse orthotopic xenograft animal model

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014328A2 (en) * 1997-09-17 1999-03-25 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6899882B1 (en) 1989-03-24 2005-05-31 The Regents Of The University Of California Endothelial cell growth factor methods of isolation and expression
US6436707B1 (en) 1998-03-27 2002-08-20 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
US6051690A (en) * 1998-04-23 2000-04-18 Genentech, Inc. NSP molecules
CA2326001A1 (en) * 1998-04-24 1999-11-04 Genentech, Inc. Fizz proteins
EP1633872A2 (en) * 1999-09-24 2006-03-15 Lexicon Genetics Incorporated Novel human protease inhibitor-like proteins and polynucleotides encoding the same
JP4211966B2 (en) * 1999-11-30 2009-01-21 ジェネンテック・インコーポレーテッド Compositions and methods for treating immune related diseases
JP2003533215A (en) 2000-05-12 2003-11-11 レキシコン ジェネティックス インコーポレーテッド Novel seven transmembrane proteins and polynucleotides encoding said proteins
AU6531101A (en) * 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002045494A2 (en) * 2000-12-06 2002-06-13 Deltagen, Inc. Transgenic mice containing glucagon receptor gene disruptions
US20040067553A1 (en) 2000-12-28 2004-04-08 Masanori Miwa Novel g protein-coupled receptor protein and dna thereof
WO2003001908A1 (en) * 2001-06-26 2003-01-09 Deltagen, Inc. Hspc150-like gene disruptions, compositions and methods related thereto
US20050233954A1 (en) * 2002-04-08 2005-10-20 Eli Lilly And Company Use of resistin to treat hematopoietic disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014328A2 (en) * 1997-09-17 1999-03-25 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9020572B2 (en) 2008-02-21 2015-04-28 Dexcom, Inc. Systems and methods for processing, transmitting and displaying sensor data
US9143569B2 (en) 2008-02-21 2015-09-22 Dexcom, Inc. Systems and methods for processing, transmitting and displaying sensor data
US11021711B2 (en) 2008-03-14 2021-06-01 Genentech, Inc. Genetic variations associated with drug resistance

Also Published As

Publication number Publication date
US20070292438A1 (en) 2007-12-20
AU2004299044B2 (en) 2008-10-30
ZA200801231B (en) 2009-05-27
CA2550117A1 (en) 2005-06-30
US8067664B2 (en) 2011-11-29
WO2005058028A2 (en) 2005-06-30
AU2008234961A1 (en) 2008-11-13
ZA200605822B (en) 2009-05-27
JP2007518404A (en) 2007-07-12
ZA200801235B (en) 2009-05-27
US20120174239A1 (en) 2012-07-05
ZA200801230B (en) 2009-05-27
EP1694116A2 (en) 2006-08-30
AU2004299044A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
WO2005058028A3 (en) Novel gene disruptions, compositions and methods relating thereto
WO2005112619A3 (en) Novel gene disruptions, compositions and methods relating thereto
Mekada et al. Substrains matter in phenotyping of C57BL/6 mice
O'Leary et al. Age‐related deterioration of motor function in male and female 5xFAD mice from 3 to 16 months of age
WO2008036437A3 (en) Novel gene disruptions, compositions and methods relating thereto
Kang et al. The mitochondrial transcription factor TFAM in neurodegeneration: emerging evidence and mechanisms
WO2007114979A3 (en) Gene disruptons, compositions and methods relating thereto
Schwaller et al. Prolonged contraction-relaxation cycle of fast-twitch muscles in parvalbumin knockout mice
Ganesh et al. Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice
Dillon et al. Increased mitochondrial biogenesis in muscle improves aging phenotypes in the mtDNA mutator mouse
Wang et al. CRISPR knockouts of pmela and pmelb engineered a golden tilapia by regulating relative pigment cell abundance
WO2006049854A3 (en) Disruptions of genes encoding secreted proteins, compositions and methods relating thereto
Martinez et al. Genomic imprinting variations in the mouse type 3 deiodinase gene between tissues and brain regions
WO2008121199A3 (en) Transgenic animal models of disease
WO2008042469A3 (en) Knockout mice for different genes and their use for gene characterizatio
Gan et al. Micro RNA‐140‐5p impairs zebrafish embryonic bone development via targeting BMP‐2
Wong et al. Differential expression of the HvCslF6 gene late in grain development may explain quantitative differences in (1, 3; 1, 4)-β-glucan concentration in barley
WO2005079566A3 (en) Gene disruptions, compositions and methods relating thereto
del Hierro et al. Potential of edible insects as a new source of bioactive compounds against metabolic syndrome
WO2007120955A3 (en) Genes affecting human memory performance
Nestor et al. Aberrant dendritic excitability: a common pathophysiology in CNS disorders affecting memory?
ATE249236T1 (en) PREDICTIVE AND THERAPEUTIC FOR KIDNEY DISEASE GENES AND PROTEINS
WO2006026222A3 (en) Novel gene disruptions, compositions and methods relating thereto
McMahon et al. Epidermal expression of an Elovl4 transgene rescues neonatal lethality of homozygous Stargardt disease-3 mice
WO2008091888A3 (en) Novel gene disruptions, compositions and methods relating thereto

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 547804

Country of ref document: NZ

Ref document number: 2550117

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004813966

Country of ref document: EP

Ref document number: 2004299044

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006545780

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2004299044

Country of ref document: AU

Date of ref document: 20041213

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004299044

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200605822

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 2004813966

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10583466

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10583466

Country of ref document: US